ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
122.898,80
1,23%
S&P 500
5.352,96
-0,02%
US Dollar vs BRL
5,2558
-0,87%
Bitcoin
70.770,38
-0,43%
Brent Oil
79,895
1,70%
Registration Strip Icon for pro Negocie como um profissional: Aproveite discussões em tempo real e ideias que movimentam o mercado para superar a concorrência.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Puma Biotechnology Inc (PBYI)

  7. Puma Biotechnology Inc (PBYI) Notícias

PBYI

Puma Biotechnology (PBYI)

Puma Biotechnology Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:PBYI
DataHoraFonteTítuloCódigoCompanhia
03/06/202415:33Business WirePuma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in Advanced EGFR-Mutated Lung CancerNASDAQ:PBYIPuma Biotechnology Inc
02/06/202411:01Business WirePuma Biotechnology Announces Presentation of Findings from a Phase II Study of Alisertib in Endocrine-Resistant Metastatic Breast Cancer (TBCRC 041)NASDAQ:PBYIPuma Biotechnology Inc
28/05/202410:00Business WirePuma Biotechnology to Join Russell 3000 IndexNASDAQ:PBYIPuma Biotechnology Inc
23/05/202418:15Business WirePuma Biotechnology Announces Publication of Alisertib Abstract Titles for the 2024 ASCO Annual MeetingNASDAQ:PBYIPuma Biotechnology Inc
17/05/202417:43Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:PBYIPuma Biotechnology Inc
02/05/202417:05Business WirePuma Biotechnology Reports First Quarter Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
18/04/202417:15Business WirePuma Biotechnology to Host Conference Call to Discuss First Quarter 2024 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
03/04/202418:30Business WirePuma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:PBYIPuma Biotechnology Inc
20/03/202409:30Business WirePuma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast CancerNASDAQ:PBYIPuma Biotechnology Inc
29/02/202418:05Business WirePuma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
22/02/202418:10Business WirePuma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care ConferenceNASDAQ:PBYIPuma Biotechnology Inc
15/02/202418:10Business WirePuma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
14/02/202420:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:PBYIPuma Biotechnology Inc
14/02/202410:19Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:PBYIPuma Biotechnology Inc
13/02/202410:30Business WirePuma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung CancerNASDAQ:PBYIPuma Biotechnology Inc
11/01/202418:07Business WirePuma Biotechnology to Present at B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:PBYIPuma Biotechnology Inc
10/01/202418:38Edgar (US Regulatory)Form 144/A - Report of proposed sale of securities: [Amend]NASDAQ:PBYIPuma Biotechnology Inc
03/01/202423:40Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:PBYIPuma Biotechnology Inc
11/12/202310:30Business WirePuma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast CancerNASDAQ:PBYIPuma Biotechnology Inc
02/11/202317:40Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:PBYIPuma Biotechnology Inc
02/11/202317:05Business WirePuma Biotechnology Reports Third Quarter 2023 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
19/10/202317:14Business WirePuma Biotechnology to Host Conference Call to Discuss Third Quarter 2023 Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
14/10/202313:30Business WirePuma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics MeetingNASDAQ:PBYIPuma Biotechnology Inc
21/09/202318:02Dow Jones NewsPuma Biotechnology Stock Up 6.9% on New FDA Orphan Drug DesignationNASDAQ:PBYIPuma Biotechnology Inc
21/09/202317:55Dow Jones NewsPuma Biotechnology Gets Orphan Designation for Small Cell Lung Cancer DrugNASDAQ:PBYIPuma Biotechnology Inc
21/09/202317:10Business WirePuma Biotechnology Receives FDA Orphan Drug Designation for Alisertib for the Treatment of Small Cell Lung CancerNASDAQ:PBYIPuma Biotechnology Inc
01/09/202311:18Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:PBYIPuma Biotechnology Inc
31/08/202317:07Business WirePuma Biotechnology to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:PBYIPuma Biotechnology Inc
08/08/202309:30Business WirePuma Biotechnology Announces FDA Clearance of IND for Alisertib in Small Cell Lung CancerNASDAQ:PBYIPuma Biotechnology Inc
03/08/202317:05Business WirePuma Biotechnology Reports Second Quarter Financial ResultsNASDAQ:PBYIPuma Biotechnology Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:PBYI

Seu Histórico Recente

BOV
IBOV
Índice Bovespa
BOV
PRIO3
PETRORIO ON
BOV
COGN3
COGNA ON
BOV
HBOR3
HELBOR ON
BOV
AZEV4
AZEVEDO PN
BOV
RCSL3
RECRUSUL ON
BOV
IFCM3
Infracommerce Caxaas ON
BOV
JHSF3
JHSF PART ON
BOV
HAGA3
HAGA ON
BOV
RCSL4
RECRUSUL PN
BOV
IDIV
Dividend
BOV
RNEW4
RENOVA PN
BOV
MGLU3
MAGAZINE LUIZA ON
BOV
PCAR3
PÃO DE AÇUCAR ON
BOV
UNIP6
UNIPAR PNB
BOV
TELB4
TELEBRAS PN
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados